Fundamental Analysis Stories

BNS
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Bank of Nova Scotia Price to Sales Ratio is relatively stable at the moment as compared to the past year. Bank of Nova Scotia reported last year Price to Sales Ratio of 2.67. As of 12/01/2020, Return on Average Assets is likely to grow to 0.007411, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop slightly above 12.6 B. If you have been following Bank of Nova Scotia you may be considering buying. Let's check if invariable basic indicators will continue to push the price to spike for Bank of Nova Scotia's retail investors. We currently estimate Bank of Nova Scotia as undervalued. The real value is approaching 51.39 per share.
EMKR
  over six months ago at Macroaxis 
By Raphi Shpitalnik
EMCORE Working Capital is relatively stable at the moment as compared to the past year. EMCORE reported last year Working Capital of 47.44 Million. As of 11/29/2020, PPandE Turnover is likely to grow to 3.46, while Revenue Per Employee is likely to drop slightly above 185.2 K. One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will sum up EMCORE. We will look into reasons why it is still very possible for the company to generate above-average returns. The entity current odds of financial distress is over 78%. Are EMCORE retail investors still optimistic?
ARTH
  over six months ago at Macroaxis 
By Ellen Johnson
ARCH THERAPEUTICS Invested Capital Average is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital Average was reported at 149,109. The current Market Capitalization is estimated to increase to about 57 M, while Average Assets are projected to decrease to roughly 3.6 M. Despite nearly stable basic indicators, ARCH THERAPEUTICS is not utilizing all of its potentials. The latest stock price disturbance, may contribute to a mid-run swings for the stockholders. The company follows the market closely. We can now examine ARCH THERAPEUTICS as a potential investment option for your portfolios.
NVAX
  over six months ago at Macroaxis 
By Achuva Shats
Novavax Accrued Expenses Turnover is fairly stable at the moment as compared to the past year. Novavax reported Accrued Expenses Turnover of 0.84 in 2019. Cash and Equivalents Turnover is likely to rise to 0.38 in 2020, whereas Net Income Per Employee is likely to drop (867.7 K) in 2020. If you have been following Novavax you may be considering acquiring. Let's check if strong basic indicators will continue to push the price to rise for Novavax's investors. Novavax current probability of bankruptcy is under 14 percent. Will investors continue to be optimistic, or should we expect a sell-off?
CHI
  over six months ago at Macroaxis 
By Achuva Shats
China Everbright Int is scheduled to announce its earnings tomorrow. Is industrials space attracting new shareholders, let's check if China Everbright Int is sending any bullish signals. We will evaluate why we are still confident in anticipation of a recovery. China Everbright Int probability of financial unrest is under 47 percent. Will China Everbright shareholders continue to purchase in December?
NJR
  over six months ago at Macroaxis 
By Ellen Johnson
NewJersey Resources Accrued Expenses Turnover is relatively stable at the moment as compared to the past year. NewJersey Resources reported last year Accrued Expenses Turnover of 101.20. As of 11/27/2020, Operating Margin is likely to grow to 5.55, while Average Assets are likely to drop slightly above 4.5 B. Even with relatively invariable technical and fundamental indicators, NewJersey Resources is not utilizing all of its potentials. The latest stock price agitation, may contribute to a short-term swings for the retail investors. We currently estimate NewJersey Resources as fairly valued. The real value is approaching 38.32 per share.
LUK
  over six months ago at Macroaxis 
By Ellen Johnson
In spite of rather unsteady technical and fundamental indicators, Luk Fook exhibited solid returns over the last few months and may actually be approaching a breakup point. The company moves indifferently to market moves. We can now discuss LKFLF as a potential investment option for your portfolios.
DKS
  over six months ago at Macroaxis 
By Raphi Shpitalnik
Dicks Sporting Goods is scheduled to announce its earnings today. The next earnings report is expected on the 9th of March 2021. Consumer cyclical space may be getting hot again, let's check if Dicks Sporting Goods is sending any bullish signals to investors. I will address the reasons this entity was abused by retail investors resulted from the current market uncertainty. We currently estimate Dicks Sporting as undervalued. The real value is approaching 61.62 per share.
MOV
  over six months ago at Macroaxis 
By Vlad Skutelnik
Movado Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. Movado reported Cash and Equivalents Turnover of 3.73 in 2019. Cash Flow Per Share is likely to climb to 1.72 in 2020, whereas Average Assets are likely to drop slightly above 786.8 M in 2020. Movado Group is scheduled to announce its earnings today. The next earnings report is expected on the 25th of March 2021. As some conservatives are trying to avoid consumer cyclical space, we'll focus on Movado Group a little further and explain its current market possibilities. We will look into reasons why it is still very possible for the company to generate above-average returns. Will sophisticated investors continue to hold, or should we expect a sell-off?